By: Susan Moench, PhD, PA-C From: oncologynurseadvisor.com Patients with a history of breast cancer experiencing hot flushes and night sweats (HFNS) reported significant improvement in related quality-of-life measures following a nurse-led cognitive behavioral therapy (CBT) intervention compared with usual care, according to results of a randomized clinical trial published in Psycho-Oncology. Hot flushes and night sweats (HFNS) are commonly experienced …
Dr. Anders on Abemaciclib in HR+ Breast Cancer With Brain Metastases
By: Carey Anders, MD From: onclive.com Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discussed the use of abemaciclib (Verzenio), a selective CDK4/6 inhibitor, in patients with hormone receptor–positive, HER2-negative metastatic brain cancer with brain metastases. In the study, 52 patients were evaluated and had a median of 4 prior systemic therapies. Of the group, 75% …
Celsion Announces IRB Approval to Begin a Clinical Study of ThermoDox® Plus High Intensity Focused Ultrasound in Breast Cancer Patients at University Medical Center Utrecht in the Netherlands
Source: Celsion CORP From: globenewswire.com An Investigator-Sponsored Phase I Safety and Feasibility Study Estimated to Begin Enrollment in the Second Half of 2019 The Study Further Reinforces the Broad Potential of ThermoDox to Treat a Range of Solid Tumors with Multiple Localized Heating Sources Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that the University Medical Center Utrecht in …
Freezing Breast Tumors Instead of Cutting Them Out
By: Cathy Cassata From: healthline.com What if we could freeze cancer in its tracks? Researchers at New York-Presbyterian and Weill Cornell Medicine are doing just that in a clinical study currently under way that uses a procedure called cryoablation to freeze breast tumors. Dr. Rache Simmons, chief of breast surgery at NewYork-Presbyterian/Weill Cornell Medical Center, and professor of Surgical Oncology …
Oasmia Pharmaceutical Announces Enrollment of First Patient in Clinical Study with Docecal, a Novel Formulation of Docetaxel
Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, announced today that the first patient has been enrolled in the Phase I clinical study of the Company’s next-generation cancer treatment candidate Docecal, to be performed internationally. Docecal was approved for clinical trials in December, 2015. Docecal is a nanoparticle and water-soluble …
ONC201 Trial Featured in 2015 ASCO Conference
Hummelstown, PA (May 26, 2015) – Oncoceutics, Inc. announced that details of a clinical phase I study in advanced solid tumors of its lead compound, ONC201, will be presented at the annual conference of the American Society of Clinical Oncology (ASCO) in Chicago on Saturday, May 30. The clinical study is being conducted at Rutgers Cancer Institute of New Jersey …
- Page 2 of 2
- 1
- 2